171 related articles for article (PubMed ID: 23517622)
1. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Shen J; Wei J; Wang H; Yue G; Yu L; Yang Y; Xie L; Zou Z; Qian X; Ding Y; Guan W; Liu B
J Transl Med; 2013 Mar; 11():73. PubMed ID: 23517622
[TBL] [Abstract][Full Text] [Related]
2. Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Yue G; Wei J; Qian X; Yu L; Zou Z; Guan W; Wang H; Shen J; Liu B
PLoS One; 2013; 8(6):e65164. PubMed ID: 23762305
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Wang L; Xie L; Wang J; Shen J; Liu B
BMC Gastroenterol; 2013 Dec; 13():173. PubMed ID: 24359226
[TBL] [Abstract][Full Text] [Related]
4. SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen.
Shen J; Wei J; Wang H; Yang Y; Yue G; Wang L; Yu L; Xie L; Sun X; Bian X; Zou Z; Qian X; Guan W; Liu B
PLoS One; 2013; 8(10):e75564. PubMed ID: 24124496
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].
Wang L; Shen J; Meng LJ; Fan WF; Wang J; Liu BR
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):418-22. PubMed ID: 24119900
[TBL] [Abstract][Full Text] [Related]
6. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
7. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Tessema M; Yingling CM; Thomas CL; Klinge DM; Bernauer AM; Liu Y; Dacic S; Siegfried JM; Dahlberg SE; Schiller JH; Belinsky SA
Oncogene; 2012 Sep; 31(37):4107-16. PubMed ID: 22158045
[TBL] [Abstract][Full Text] [Related]
8. Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer.
Hur K; Han TS; Jung EJ; Yu J; Lee HJ; Kim WH; Goel A; Yang HK
J Pathol; 2012 Sep; 228(1):88-98. PubMed ID: 22653794
[TBL] [Abstract][Full Text] [Related]
9. Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.
Buhl IK; Gerster S; Delorenzi M; Jensen T; Jensen PB; Bosman F; Tejpar S; Roth A; Brunner N; Hansen A; Knudsen S
PLoS One; 2016; 11(5):e0155123. PubMed ID: 27171152
[TBL] [Abstract][Full Text] [Related]
10. ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Subhash VV; Tan SH; Yeo MS; Yan FL; Peethala PC; Liem N; Krishnan V; Yong WP
Mol Cancer Ther; 2016 Dec; 15(12):3087-3096. PubMed ID: 27638859
[TBL] [Abstract][Full Text] [Related]
11. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
[TBL] [Abstract][Full Text] [Related]
12. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts.
Robles AJ; Kurmasheva RT; Bandyopadhyay A; Phelps DA; Erickson SW; Lai Z; Kurmashev D; Chen Y; Smith MA; Houghton PJ
Clin Cancer Res; 2020 Jun; 26(12):3012-3023. PubMed ID: 32184294
[TBL] [Abstract][Full Text] [Related]
15. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
16. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J; Nishina T; Yamada Y; Moriwaki T; Shimoda T; Kajiwara T; Nakajima TE; Kato K; Hamaguchi T; Shimada Y; Okayama Y; Oka T; Shirao K
Br J Cancer; 2008 Feb; 98(4):832-9. PubMed ID: 18231104
[TBL] [Abstract][Full Text] [Related]
17. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
Braun MS; Richman SD; Quirke P; Daly C; Adlard JW; Elliott F; Barrett JH; Selby P; Meade AM; Stephens RJ; Parmar MK; Seymour MT
J Clin Oncol; 2008 Jun; 26(16):2690-8. PubMed ID: 18509181
[TBL] [Abstract][Full Text] [Related]
19. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Yashiro M; Nishii T; Hasegawa T; Matsuzaki T; Morisaki T; Fukuoka T; Hirakawa K
Br J Cancer; 2013 Nov; 109(10):2619-28. PubMed ID: 24129235
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
